Hillary Clinton Predictably Uses 4th of July to Defend Her “Progressive” Record

“As 2016 presidential candidates flocked to spend Independence Day in early voting states such as Iowa and New Hampshire, Democratic frontrunner Hillary Clinton found herself defending her record on policy and the size of crowds at her events.”

Continue reading


Democrats Who Voted for Fast Track Legislation

Photo courtesy of action.workingfamilies.org

Photo courtesy of action.workingfamilies.org

Barack Obama was given the authority he has long sought to expedite negotiations for a massive trade deal with countries on the Pacific rim, propelling the US toward a landmark agreement that, both proponents and critics agree, will reshape the global economy.”

Continue reading

What Voters Should Know About Hillary Clinton

Photo courtesy of wikimedia.org

Photo courtesy of wikimedia.org

On June 13 in New York City, Hillary Clinton officially launched her presidential campaign.

“Democracy can’t be just for billionaires and corporations,” she yelled to the crowd of excited spectators and supporters (billmoyers.com).

Continue reading

Expense of new Hepatitis C drug casts a bad light on U.S. Health Care system

Tanya’s Comment: The over-charging of life saving medications needs to stop.

The Secular Jurist

By Robert A. Vella

High demand means high prices.  That’s the system of capitalism which dominates our world today.  In theory, market competition rises in proportion to growing demand which exerts downward pressure on prices through innovation and increased efficiency.  However, reality often doesn’t match theory in the realm of economics especially in the U.S.  Enabled by the de facto practice of corporatism, business interests can monopolize markets, drive out the competition, and exploit consumers and workers.  In the health care industry, this leads to exorbitant costs that can limit or exclude vital medical services from whole groups of sick and injured people.

Such is the case now with a new and effective hepatitis C drug called Sovaldi.

From Reuters (March 21, 2014) – U.S. lawmakers want Gilead to explain Sovaldi’s hefty price:

(Reuters) – U.S. lawmakers have asked Gilead Sciences Inc to explain the $84,000 price…

View original post 433 more words